TERN

TERN

USD

Terns Pharmaceuticals Inc. Common Stock

$17.430+1.930 (12.452%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$15.500

最高

$18.740

最低

$15.500

交易量

4.37M

公司基本面

市值

1.5B

行業

生物科技

國家

United States

交易統計

平均交易量

1.85M

交易所

NMS

貨幣

USD

52週範圍

最低 $1.865當前 $17.430最高 $18.74

相關新聞

Analyst Upgrades

Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28

Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma with a Buy and raises the price target from $20 to $28.

查看更多
Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28
Analyst Upgrades

BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22

BMO Capital analyst Etzer Darout maintains Terns Pharma with a Outperform and raises the price target from $15 to $22.

查看更多
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22
Analyst Upgrades

Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27

Barclays analyst Etzer Darout maintains Terns Pharma with a Overweight and raises the price target from $14 to $27.

查看更多
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27
Analyst Upgrades

HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma from Neutral to Buy and announces $20 price target.

查看更多
HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target
Analyst Upgrades

William Blair Upgrades Terns Pharma to Outperform

William Blair analyst Andy Hsieh upgrades Terns Pharma from Market Perform to Outperform.

查看更多
William Blair Upgrades Terns Pharma to Outperform
Analyst Upgrades

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

GlobeNewswire

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on